Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 10: The Cardiac Channelopathies

Authors, Journal, Affiliations, Type, DOI

Overview

The Task Force 10 statement sets the 2015 AHA/ACC position on competitive sports participation for athletes with the six cardiac channelopathies — long-QT syndrome, catecholaminergic polymorphic ventricular tachycardia, Brugada syndrome, early repolarization syndrome, short-QT syndrome and idiopathic ventricular fibrillation. It replaces the post-2005 recommendation that restricted athletes with any channelopathy from all competitive sport with a phenotype-graded scheme in which only previously symptomatic athletes (Class I restriction) and CPVT with exercise-induced ventricular ectopy (Class III) are actually excluded; concealed genotype-positive athletes are cleared at Class IIa and manifest disease is cleared at Class IIb. The shift rests on four developments the writing group lists explicitly, including the first observational data from athletes with LQTS who remained competitive against advice (>650 athlete-years with a single appropriate shock), and it is candid that every recommendation is Level of Evidence C. The statement remains the historical reference point against which the 2025 AHA/ACC shared-decision-making framework is measured.

Keywords

Athletes · Brugada syndrome · Cardiovascular abnormalities · Channelopathies · Heart rhythm disorders · Long QT syndrome · Competitive sports · Disqualification · Shared decision-making

Key Takeaways

Scope and Definitions

The 2005 Position and the Four Developments Since

Precautionary Measures

Applies to every participating athlete with a channelopathy, concealed or manifest:

Recommendations

# Recommendation Class LOE
1 Comprehensive evaluation by a heart rhythm specialist or genetic cardiologist with sufficient channelopathy expertise I C
2 Symptomatic athletes with any suspected or diagnosed channelopathy restricted from all competitive sport until evaluation is complete, the athlete and family are informed, treatment is implemented, and the athlete has been asymptomatic on therapy for 3 months I C
3 Asymptomatic genotype-positive/phenotype-negative LQTS, CPVT, BrS, ERS, IVF or SQTS: participation in all competitive sport with precautionary measures IIa C
4 Previously symptomatic or ECG-evident BrS, ERS or SQTS: participation may be considered with precautionary measures and disease-specific treatment, asymptomatic on treatment ≥3 months IIb C
5 Symptomatic or ECG-manifest LQTS (QTc >470 ms in males, >480 ms in females): participation may be considered after treatment and precautionary measures, asymptomatic on treatment ≥3 months — except competitive swimming in a previously symptomatic LQT1 host IIb C
6 Previously symptomatic CPVT, or asymptomatic CPVT with exercise-induced bigeminy, couplets or NSVT: competitive sport not recommended except class IA sports (low static and low dynamic demand); exceptions only after CPVT specialist consultation III C

Epidemiology Given

Limitations of the document

Key Concepts Mentioned

Key Entities Mentioned

Wiki Pages Updated